TAK
Takeda Pharmaceutical·NYSE
--
--(--)
--
--(--)
TAK fundamentals
Takeda Pharmaceutical (TAK) Revenue Breakdown: Q1 2026 Business & Regional Performance
Takeda Pharmaceutical (TAK) reported total revenue of 7.68B USD in Q1 2026, with its core business segment Gastroenterology contributing 30.66%. Regionally, Japan remained the largest market, accounting for 9.76% of total revenue. Explore Takeda Pharmaceutical's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
Takeda Pharmaceutical (TAK) reported total revenue of 7.68B USD in Q1 2026, with its core business segment Gastroenterology contributing 30.66%. Regionally, Japan remained the largest market, accounting for 9.76% of total revenue. Explore Takeda Pharmaceutical's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
By Business
No Data
By Region
No Data
You can ask Aime
What is the revenue and EPS growth rate for Takeda Pharmaceutical year over year?Did Takeda Pharmaceutical beat or miss consensus estimates last quarter?What guidance did Takeda Pharmaceutical's management provide for the next earnings period?What does Takeda Pharmaceutical do and what are its main business segments?What were the key takeaways from Takeda Pharmaceutical's earnings call?What were the key takeaways from Takeda Pharmaceutical’s earnings call?What is the market's earnings forecast for Takeda Pharmaceutical next quarter?What factors drove the changes in Takeda Pharmaceutical's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
